Literature DB >> 22230905

IBD in 2011: Advances in IBD management--towards a tailored approach.

Guillaume P Pineton de Chambrun1, William J Sandborn.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22230905     DOI： 10.1038/nrgastro.2011.248

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease.

Authors:  Jeffrey C Barrett; Sarah Hansoul; Dan L Nicolae; Judy H Cho; Richard H Duerr; John D Rioux; Steven R Brant; Mark S Silverberg; Kent D Taylor; M Michael Barmada; Alain Bitton; Themistocles Dassopoulos; Lisa Wu Datta; Todd Green; Anne M Griffiths; Emily O Kistner; Michael T Murtha; Miguel D Regueiro; Jerome I Rotter; L Philip Schumm; A Hillary Steinhart; Stephan R Targan; Ramnik J Xavier; Cécile Libioulle; Cynthia Sandor; Mark Lathrop; Jacques Belaiche; Olivier Dewit; Ivo Gut; Simon Heath; Debby Laukens; Myriam Mni; Paul Rutgeerts; André Van Gossum; Diana Zelenika; Denis Franchimont; Jean-Pierre Hugot; Martine de Vos; Severine Vermeire; Edouard Louis; Lon R Cardon; Carl A Anderson; Hazel Drummond; Elaine Nimmo; Tariq Ahmad; Natalie J Prescott; Clive M Onnie; Sheila A Fisher; Jonathan Marchini; Jilur Ghori; Suzannah Bumpstead; Rhian Gwilliam; Mark Tremelling; Panos Deloukas; John Mansfield; Derek Jewell; Jack Satsangi; Christopher G Mathew; Miles Parkes; Michel Georges; Mark J Daly
Journal:  Nat Genet       Date:  2008-06-29       Impact factor: 38.330

Review 2.  Clinical implications of mucosal healing for the management of IBD.

Authors:  Guillaume Pineton de Chambrun; Laurent Peyrin-Biroulet; Marc Lémann; Jean-Frédéric Colombel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-12-01       Impact factor: 46.802

3.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.

Authors:  Jean Frédéric Colombel; Paul Rutgeerts; Walter Reinisch; Dirk Esser; Yanxin Wang; Yinghua Lang; Colleen W Marano; Richard Strauss; Björn J Oddens; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Daniel Present; Bruce E Sands; William J Sandborn
Journal:  Gastroenterology       Date:  2011-06-30       Impact factor: 22.682

4.  Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.

Authors:  Edouard Louis; Jean-Yves Mary; Gwenola Vernier-Massouille; Jean-Charles Grimaud; Yoram Bouhnik; David Laharie; Jean-Louis Dupas; Hélène Pillant; Laurence Picon; Michel Veyrac; Mathurin Flamant; Guillaume Savoye; Raymond Jian; Martine Devos; Raphaël Porcher; Gilles Paintaud; Eric Piver; Jean-Frédéric Colombel; Marc Lemann
Journal:  Gastroenterology       Date:  2011-09-22       Impact factor: 22.682

5.  Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.

Authors:  Gert Van Assche; Séverine Vermeire; Vera Ballet; Frederik Gabriels; Maja Noman; Geert D'Haens; Christophe Claessens; Evelien Humblet; Niels Vande Casteele; Ann Gils; Paul Rutgeerts
Journal:  Gut       Date:  2011-09-23       Impact factor: 23.059

6.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.

Authors:  Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar
Journal:  Gut       Date:  2011-01-05       Impact factor: 23.059

7.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

8.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

9.  Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study.

Authors:  Jessica Coelho; Laurent Beaugerie; Jean Frédéric Colombel; Xavier Hébuterne; Eric Lerebours; Marc Lémann; Philippe Baumer; Jacques Cosnes; Arnaud Bourreille; Jean Pierre Gendre; Philippe Seksik; Antoine Blain; Etienne H Metman; Andrée Nisard; Guillaume Cadiot; Michel Veyrac; Benoît Coffin; Xavier Dray; Fabrice Carrat; Philippe Marteau
Journal:  Gut       Date:  2010-11-29       Impact factor: 23.059

10.  Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Authors:  Laurent Beaugerie; Nicole Brousse; Anne Marie Bouvier; Jean Frédéric Colombel; Marc Lémann; Jacques Cosnes; Xavier Hébuterne; Antoine Cortot; Yoram Bouhnik; Jean Pierre Gendre; Tabassome Simon; Marc Maynadié; Olivier Hermine; Jean Faivre; Fabrice Carrat
Journal:  Lancet       Date:  2009-11-07       Impact factor: 79.321
  10 in total
  3 in total

Review 1.  Insights into the role of progranulin in immunity, infection, and inflammation.

Authors:  Jinlong Jian; Jessica Konopka; Chuanju Liu
Journal:  J Leukoc Biol       Date:  2012-10-22       Impact factor: 4.962

2.  Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission.

Authors:  Michelle G Rooks; Patrick Veiga; Leslie H Wardwell-Scott; Timothy Tickle; Nicola Segata; Monia Michaud; Carey Ann Gallini; Chloé Beal; Johan E T van Hylckama-Vlieg; Sonia A Ballal; Xochitl C Morgan; Jonathan N Glickman; Dirk Gevers; Curtis Huttenhower; Wendy S Garrett
Journal:  ISME J       Date:  2014-02-06       Impact factor: 10.302

3.  Modulation of Gut Microbiome Composition and Function in Experimental Colitis Treated with Sulfasalazine.

Authors:  Haihui Zheng; Mingyi Chen; Yuan Li; Yuanyuan Wang; Lin Wei; Ziqiong Liao; Mengxia Wang; Fangli Ma; Qiongfeng Liao; Zhiyong Xie
Journal:  Front Microbiol       Date:  2017-09-07       Impact factor: 5.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.